Eradication therapy for early Pseudomonas aeruginosa infection in CF: Many questions still unanswered

European Respiratory Journal

Volumn 26, Issue 3, 2005, Pages 373-375

  Jones, Andrew M ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GENTAMICIN; PLACEBO; PSEUDOMONAS VACCINE; TOBRAMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DRUG ADMINISTRATION ROUTE; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; EDITORIAL; ERADICATION THERAPY; EUROPE; FOLLOW UP; HIGH RISK PATIENT; HOSPITAL HYGIENE; HUMAN; INFECTION CONTROL; ITALY; MEDICAL LITERATURE; MEDICAL SOCIETY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REINFECTION; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

EID: 24644491231     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00069705     Document Type: Editorial

References (22)

1. Pamukcu A, Bush A, Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthrometric variables in children with cystic fibrosis. Pediatr Pulmonol 1995; 19: 10-15.
2. Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001; 32: 277-287.
3. Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001; 138: 659-704.
4. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992; 12: 158-161.
5. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23: 330-335.
6. Taccetti G, Campana S, Festini F, Mascherini M, Doring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005; 26: 458-461.
7. Littlewood JM, Miller MG, Ghonheim AT, Ramden CH. Nebulised colomycin for early Pseudomonas colonisation in cystic fibrosis. Lancet 1985; 1: 865.
8. Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B, Doring G. Placebo-controlled double blind randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis. Pediatr Pulmonol 1998; 25: 88-92.
9. Ratjen F, Doring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001; 358: 983-984.
10. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 841-849.
11. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa infection in cystic fibrosis by early treatment. Lancet 1991; 338: 725-726.
12. Munck A, Bonacorsi S, Mariani-Kurkdijan P, et al. Geno-typic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol 2001; 32: 288-292.
13. Doring G, Conway SP, Heijerman HGM, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000; 16: 749-767.
14. Heinzl B, Eber E, Oberwaldenr B, Haas G, Zach MS. Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study. Pediatr Pulmonol 2002; 33: 32-37.
15. Govan JRW, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996; 60: 539-574.
16. Cheng K, Smyth RL, Govan JR, et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996; 348: 639-642.
17. Jones AM, Govan JR, Doherty CJ, et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 2001; 358: 557-558.
18. McCallum SJ, Corkill J, Gallagher M, Ledson MJ, Hart CA, Walshaw MJ. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P aeruginosa. Lancet 2001; 358: 558-560.
19. Armstrong DS, Nixon GM, Carzino R, et al. Detection of a widespread clone of Pseudomonas aeruginosa in a paediatric cystic fibrosis clinic. Am J Respir Crit Care Med 2002; 166: 983-987.
20. O'Carroll MR, Syrmis MW, Wainwright CE, et al. Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. Eur Respir J 2004; 24: 101-106.
21. Scott FW, Pitt TL. Identification and characterisation of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales. J Med Microbiol 2004; 53: 609-615.
22. Lee TWR, Brownlee KG, Denton M, Littlewood JM, Conway SP. Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional paediatric cystic fibrosis center. Pediatr Pulmonol 2004; 37: 104-110.